2008
DOI: 10.1136/ard.2008.088773
|View full text |Cite
|
Sign up to set email alerts
|

Anti-tumour necrosis factor   therapy modulates ghrelin in patients with severe rheumatoid arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

12
106
0
2

Year Published

2009
2009
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 85 publications
(120 citation statements)
references
References 6 publications
12
106
0
2
Order By: Relevance
“…In this regard, Lacerda et al (30) demonstrated that TNF knockout mice with streptozotocin-induced diabetes have a favorable effect on glycemic control. Furthermore, glycemic control improved after the administration of ETN in rheumatoid arthritis patients with concomitant diabetes (22). Thus, we cannot exclude the possibility that ETN might have ameliorated nephropathy through the improvement of glycemic control, although ETN did not alter adiponectin levels.…”
Section: Discussionmentioning
confidence: 84%
“…In this regard, Lacerda et al (30) demonstrated that TNF knockout mice with streptozotocin-induced diabetes have a favorable effect on glycemic control. Furthermore, glycemic control improved after the administration of ETN in rheumatoid arthritis patients with concomitant diabetes (22). Thus, we cannot exclude the possibility that ETN might have ameliorated nephropathy through the improvement of glycemic control, although ETN did not alter adiponectin levels.…”
Section: Discussionmentioning
confidence: 84%
“…Furthermore, visfatin was not associated with inflammation in patients with severe RA undergoing anti-TNF-α therapy (20). Another study reported that anti-TNF-α therapy resulted in a rapid reduction in serum resistin levels, but did not modulate leptin levels in RA patients (21). It was also demonstrated that serum leptin concentrations are inversely correlated with inflammation in RA (22).…”
Section: Discussionmentioning
confidence: 99%
“…Very recently, a decline in serum levels of resistin after TNF-α blocking therapy has been shown; it is evident that this therapy, in addition to reducing joint inflammation, can concomitantly improve the cardiovascular prognosis in inflammatory disorders [108,109]. An association between serum resistin levels, inflammation, bone mineral density, and renal functions has been demonstrated in patients with systemic lupus erythematosus (SLE) [110].…”
Section: Resistin In Rheumatic Diseasesmentioning
confidence: 99%
“…Resistin significantly decreased after the TNF-α blocking therapy in patients with rheumatoid arthritis and inflammatory bowel disease [108,109,123]. Treatment of patients with the skin form of psoriasis with retinoids leads to a normalization of serum resistin levels [113].…”
Section: Resistin As a Potential Pharmacological Targetmentioning
confidence: 99%